Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model.NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. Today, NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also in the experimental MCD NASH model, strengthening and confirming

Citycon Q1: Good start to the year – EPRA Earnings growth fuelled by Sweden and Norway

Citycon Oyj      Interim Report      20 April 2017 at 09:00 hrsJANUARY—MARCH 2017-Net rental income increased to EUR 56.6 million (Q1/2016: 55.2) mainly due to (re)development projects coming online (mainly Iso Omena) and the acquisition of the adjacent building to Citycon’s Oasen shopping centre in Bergen, Norway. In addition, positive like-for-like growth contributed to net rental income growth by EUR 0.5 million. The non-core property divestments in 2016 and 2017 decreased net rental income by EUR 2.0 million.-EPRA Earnings increased by EUR 2.4 million, or 6.6%, to EUR 38.3 million,

Interim Report Q1 2017

Financial overview Q1 2017 · Total net revenues SEK 127.4 million (151.0) · Zubsolv® net revenue SEK 114.1 million (98.4) · EBIT SEK -23.2 million (-26.2) · EBITDA SEK -18.1 million (-19.4) · Earnings per share, before and after dilution, SEK -1.00/-1.00 (-1.00/-1.00) · Cash flow from operating activities SEK 28.2 million (33.5) · Cash and cash equivalents SEK 250.6 million (233.0) · Guidance issued in connection with Full Year Report 2016 confirmed Other highlights Q1 2017 · Completion of another bond buyback program amounting to a nominal value of SEK 59

Evolution Gaming: Interim report January-March 2017

First quarter of 2017 (Q1 2016) · Operating revenues increased by 60% to EUR 39.7 million (24.8) · EBITDA increased by 65% to EUR 17.0 million (10.3), corresponding to a margin of 43% (42) · Profit for the period amounted to EUR 12.7 million (7.6) · Earnings per share amounted to EUR 0.35 (0.21) Events during the first quarter of 2017 · Overall very high demand for Live Casino games among the customers · Agreement with the Spanish gaming operator Codere for exclusive provision of Live Casino in Mexico · Additional new agreements with mybet, Matchbook and White

Skanska leases office space in Generation Park in Warsaw, Poland, to Citi Service Center Poland

Skanska has leased 13,600 square meters of office space in phase I of Generation Park in Warsaw, Poland, to Citibank Europe PLC (Citi Service Center Poland). The start date of the lease is scheduled for the fourth quarter of 2017.The first phase of Generation Park is already over 70 percent leased to three tenants. Citibank will occupy about 60 percent of phase I. Generation Park will be Skanska’s largest office development in Central and Eastern Europe. The complex will comprise of three office buildings with total leasable area of around 84,000 square meters. The project is expected to

Statement by Vigmed’s bid committee in relation to the increased public offer by Greiner Bio-One

Helsingborg, 20 April 2017 The independent Vigmed Bid Committee continues to recommend the shareholders to accept the Greiner Bio-One’s public offer.On 27 February 2017, Greiner Bio-One GmbH (“GBO”) announced a public cash offer to the shareholders of Vigmed Holding AB (publ) (“Vigmed”) at the price of SEK 1.00 in cash per share (the “Offer”).On 13 April 2917, GBO announced its decision to increase the Offer consideration to SEK 1.20 in cash per share[1]. The total value of the increased Offer, based on all outstanding 65,749,998 shares in Vigmed, amounts to approximately SEK 78.9

Revenio Group Corporation: Interim report January 1 - March 31, 2017

Revenio Group Corporation, Interim Report, April 20, 2017 at 9:00 am Revenio Group Corporation Interim Report January 1 - March 31, 2017 Due to an amendment to the Securities Market Act, which came into force on November 26, 2015, the descriptive sections of Revenio's interim reports Q1/2017 and Q1-Q3/2017 will be shorter and more concise. The table sections will be reported in accordance with previous practices. The figures are unaudited. Revenio Group Corporation has adopted the publication procedure enabled by the Financial Supervisory Authority's Regulations and guidelines 7/

Mycronic receives a repeat multipleorder for the MY600 Jet Printer

Täby, 20 April, 2017 – Mycronic AB (publ), has received the third order for several MY600 Jet Printer systems. This is a repeat order from a customer that runs a high-volume consumer application running 24-hour production. Deliveries will take place during the second half-year of 2017. Mycronic’s business area Assembly Solutions offers advanced production solutions for modern electronics manufacturing. The offering comprises production equipment for non-contact application of solder paste on circuit boards, dispensing and conformal coating systems, assembly equipment for placement of

Björn Borg Annual Report 2016

The Björn Borg Annual Report for 2016 is now available at https://corporate.bjornborg.com/en/section/investors/annual-reports/As previously communicated, the Björn Borg Annual General Meeting will be held on May 11, 2017, at the Björn Borg Head Quarters, Tulegatan 11, 113 53 Stockholm. Please register for the AGM through the company website at https://corporate.bjornborg.com/en/annual-general-meeting-2017/ An English translation of the Annual Report will be uploaded to the website on May 11 at the latest. For further information, please contact: Daniel Grohman, CFO, phone: +46-850

Interim report January–March 2017

Quote from Per Eriksson, President and CEO- ”We continued to deliver on our growth strategy in the first quarter and revenues increased in line with our earlier comments about the quarter. For the first time, NetEnt’s games were launched on the regulated market in Mexico and the Company announced that the first game for Virtual Reality (VR) will be developed in 2017. For the rest of 2017, we see conditions for continued solid growth supported by new games, increasing market shares in the UK, mobile growth, many new customers to be launched and our ongoing expansion in North America.”

Skanska sells the office building Piren2 in Gothenburg, Sweden, for about SEK 410M

Skanska has sold the office building Piren2 in Gothenburg, Sweden, to Platzer Fastigheter AB for about SEK 410M. The divestment will be recorded by Skanska Commercial Development Nordic in the second quarter of 2017. The transfer of the property is preliminary scheduled for 29 September 2017.The office building of about 9,000 square meter is fully leased to Zenuity AB, a joint venture between Volvo Cars and Autoliv. Piren2 is located in the center of one of Europe's leading technology clusters, next to Lindholmen Science Park and the Radisson Blu Riverside Hotel. The building is

Fiskars’ restated segment information for 2016 according to the new organizational structure

Fiskars CorporationStock Exchange ReleaseApril 20, 2017 at 8:30 EEST  Fiskars’ restated segment information for 2016 according to the new organizational structure  Fiskars has today published restated quarterly segment information for the year 2016 concerning the new primary reporting segments: Living, Functional and Other segment as well as the geographical segments Europe, Americas, and Asia-Pacific.  As announced on November 10, 2016, Fiskars has changed its organizational structure with the aim to leverage the full potential of its strong brands, build company-wide

Elisa’s Interim Report January–March 2017

ELISA CORPORATION INTERIM REPORT RELEASE 20 APRIL 2017 AT 8:30 AM First quarter 2017 · Revenue amounted to EUR 416 million (390) · EBITDA was EUR 144 million (137), and EBIT was EUR 89 million (84) · Profit before taxes amounted to EUR 84 million (77) · Earnings per share were EUR 0.43 (0.39) · Cash flow after investments was EUR 63 million (64) · Mobile ARPU was EUR 17.2 (17.0 in previous quarter) · Mobile churn was 18.5 per cent (18.2 in previous quarter) · Mobile service revenue increased by 5.5 per cent to EUR 196 million (186) · The number of Elisa’s

Growing again

CEO Per Lindberg comments on the development during Q1 2017: “The first quarter of 2017 saw growth on the back of high demand in the markets across all business areas. Sales are showing better than expected growth, and our production is in fact at an all-time high for a single quarter. However, our operating profit during the quarter suffered from spillover effects from 2016, and we have as a consequence undertaken significant measures to address both our start-up performance as well as quality performance. Two of the key elements in our growth strategy and production capacity are our

Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform

First patient enrolled in a Phase Ib trial in patients with locally recurrent RAS-mutated rectal cancer Oslo, 20 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that it has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer scheduled to have surgery. The trial is being conducted at clinical sites in Australia and New Zealand. In this open label, non-randomized trial, ten

Good growth and stable profitability

President and CEO Klas Balkow’s comments on the first quarter:− Axfood showed good growth in an otherwise soft market. With sales growth of more than 3%, Axfood gained additional market shares during the first quarter. All concepts continued to grow and showed stable profitability.          During the quarter we increased our e-commerce initiatives. The integration of mat.se is being carried out with full strength, and more customers can shop online from Willys and Hemköp. This gives us favourable conditions to strengthen our position in the rapidly growing online segment. First

INTERIM REPORT January–March 2017

(Tables included in attached PDF)Q1 2017 · Net sales SEK 5 636 m · EBITDA SEK 923 m · EBITDA margin 16% · Earnings per share SEK 1.94 KEY HIGHLIGHTS · BillerudKorsnäs reached all-time high sales- and production volumes for a single quarter. · Net sales have increased with 5% compared to the same period previous year as a result of volume growth. · EBITDA margin for the quarter was 16% which is lower than the previous year’s 19%. EBITDA was burdened with SEK 80 million of one-off costs for quality issues and extra costs for mill re-build. · EBITDA was also

Fungi have enormous potential for new antibiotics

Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from nature’s own resources. The findings – which could prove very useful in the battle against antibiotic resistance – were recently published  in the journal, Nature Microbiology. Antibiotics have saved millions of lives since they were discovered in the 1940s. But recently we’ve had to learn a new term: antibiotic resistance. More and more

Decision on share repurchases by Axfood’s board

The Board of Directors of Axfood has decided to exercise the authorization granted to it by the Annual General Meeting on 15 March 2017 to repurchase own shares. At the time of publication of this press release Axfood has no holdings of treasury shares. Purchases may take place on one or more occasions during the period 15 May 2017 until the next Annual General Meeting, of a maximum of 200,000 shares. Repurchases shall be made on Nasdaq Stockholm at a price per share that is within the registered price interval at any given time, i.e., the interval between the highest buying price and

ABB continues its transformation

Zurich, Switzerland, April 20, 2017 - Delivers higher revenues, base orders and net income· Revenues up 3 percent · Base order growth of 2 percent · Total orders reflects lower large contract awards; book to bill ratio 1.07x · Operational EBITA margin 12.1%; solid operating leverage considering 60 bps positive insurance reserve adjustment in 2016 · Net income $724 million versus $500 million; operational EPS +1% · Cash flow from operating activities $509 million reflects delay of incentive payments caused by the South Korea case · Active portfolio management: high-voltage

Vattenfall broadens customer offer in Sweden with geothermal energy

Vattenfall currently offers its private customers several alternatives for heating their homes, such as district heat and air heat pumps. They now have an additional alternative as the company complements its offer with geothermal energy.“Geothermal energy is a good complement for owners of single houses in locations beyond the reach of our district heating network and for those who prefer a different solution. It makes us even more customer-oriented and takes us an important step closer to becoming a full-range supplier of heating solutions. It also complements our offer of local energy

Archer Limited : Preliminary result of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SUBSCRIBE OR PURCHASE ANY OF THE SECURITIES DESCRIBED HEREIN Subsequent Offering - Preliminary result Reference is made to the previous announcements by Archer Limited (the "Company") regarding the subsequent offering of up to 16,800,000 new shares in the Company (the "Subsequent Offering"). The Company hereby announces the preliminary

Rejlers wins design of stations for Statnett in North Norway

Statnett SF has commissioned Rejlers to design new transformer stations for the 420kV network in North Norway. Rejlers shall create a technical solution proposal for the stations up to the investment decision.The design commission includes electrical power, construction, geotechnics, ground surveys and roads.The work shall be carried out in the first half of 2017 and the contract contains further options on the remaining design work up to completion of the transformer stations.“We are pleased about the trust that Statnett has placed in us and are confident that we will provide optimal

There are no items matching the current filter
There are no more items matching the current filter
Back to top